Am­gen, Sanofi and Mer­ck an­nounce a string of deals at #JPM17; Mc­Do­nough out at So­bi

• Am­gen has tied the knot with Ger­many’s Im­mat­ics, pay­ing $30 mil­lion up­front and of­fer­ing hun­dreds of mil­lions more in pos­si­ble mile­stones for the de­vel­op­ment of bis­pe­cif­ic T cell-en­gag­ing ther­a­peu­tics for a range of can­cers.

• Just weeks af­ter Im­muNext signed Roche up as a part­ner, Sanofi has stepped on board to part­ner on a pre­clin­i­cal CD40L an­ti­body for au­toim­mune dis­ease that has po­ten­tial in treat­ing mul­ti­ple scle­ro­sis and lu­pus. The deal is worth a po­ten­tial $500 mil­lion, though it like­ly starts out on the small side.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER